About Enamine
Enamine is a company based in Kyiv (Ukraine) founded in 1991. Enamine offers products and services including Building Blocks Catalog, Compound Libraries, and Custom Synthesis. Enamine operates in a competitive market with competitors including Sai Life Sciences, Acies Bio, Personal Chemistry, IRBM and NFIL, among others.
- Headquarter Kyiv, Ukraine
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enamine Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.35 M (USD), Grant
Apr 01, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enamine
Enamine offers a comprehensive portfolio of products and services, including Building Blocks Catalog, Compound Libraries, and Custom Synthesis.
Catalog of over 300 thousand compounds for synthesis and research.
Pre-plated libraries for targeted drug discovery applications.
Tailored chemical synthesis using advanced technologies.
People of Enamine
Unlock access to complete
Funding Insights of Enamine
Investors in Enamine
Enamine has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Enamine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enamine
Investment portfolio details for Enamine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enamine
Detailed financials for Enamine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enamine Comparisons
Peer comparison for Enamine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enamine
Enamine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sai Life Sciences, Acies Bio, Personal Chemistry, IRBM and NFIL, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Provider of drug discovery and development services to pharmaceutical, biotech, and food industries
|
|
| Locked | Locked | Locked |
Coherent Synthesis is developed for medicinal and combinatorial chemistry applications.
|
|
| Locked | Locked | Locked |
Integrated drug discovery and preclinical development services are provided.
|
|
| Locked | Locked | Locked |
Fluorinated compounds are synthesized and manufactured customly for various industries.
|
|
| Locked | Locked | Locked |
Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry
|
Detailed competitors of Enamine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enamine
Complete news archive for Enamine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enamine
Enamine was founded in 1991 and raised its 1st funding round 25 years after it was founded.
Enamine is headquartered in Kyiv, Ukraine.
David Leahy is the current CEO of Enamine.
Enamine is a drug discovery CRO offering a range of products and services for facilitating drug discovery and preclinical development. Their major products include screening compounds and building blocks which include over 2.2 million compounds (which include 27,000 fragments and 175,000 building blocks), while their major services include custom synthesis, lead optimization, and molecular modeling. Enamine has several compound libraries for fragment-based drug discovery (Rule of three, Golden fragment, fluorinated, brominated libraries, among several others), focused and targeted drug discovery (Ex: CNS-targeted, Nuclear receptor and Ion-channel libraries, among several others) and express lead-based drug discovery (novel lead-like libraries synthesised and delivered in 2-3 weeks). Enamines service portfolio includes Hit Follow-Up Support, Custom synthesis (Small molecules, intermediates, reference compounds, fragment libraries etc), bioanalytical and HTS screening services (through its subsidiary Bienta, which offers in vitro ADMET and pharmacokinetic assays (biochemical and cell-based assays)). Enamine has a partnership with Ukrainian company FCH Group for compound library synthesis. Actelions RD Spinoff, RD NewCo signed an agreement with Enamine in January 2017 for access to its novel building blocks and screening libraries for use in early drug discovery.
Enamine's top competitors include Sai Life Sciences, Acies Bio and Liverpool ChiroChem.
Enamine offers Building Blocks Catalog, Compound Libraries, and Custom Synthesis.
Enamine has 1 investor. Key investors include European Union.